PTPN11 and cancer: As RAS-driven cancers were considered undruggable until recently and still represent a clinical challenge, the discovery that some oncogenic RAS mutants that still undergo a GTP cycle require SHP2 for GTP loading spurred the development of SHP2 inhibitors.